The project formally rolled out its human albumin and human immunoglobulin (pH4) for intravenous injection on Nov 12 and 13, respectively.

In an interview, Yang Huichuan, chief scientist and vice-chairman of CNBG, said that Yunnan is crucial for Sinopharm to further expand its presence in southwestern China and Southeast Asia. It has a huge potential in the development of biopharmaceutical industry.

According to Liu Ya'na, Party secretary and deputy general-manager of Beijing Tiantan Biological Products and executive director of Sinopharm Kunming Plasma-Derived Biotherapies, the formal operation of the project has filled the gap of Yunnan in the manufacture of plasma-derived medicinal products. It will support the development of blood product manufacturing sector in the province, address domestic shortage of plasma-derived medicinal products, reduce the import of commodities from other countries, and advance the country's biological and medical security.

Yang added that Beijing Tiantan Biological Products will accelerate the full production of the industrial project, and work together with local governments to drive the further development of biological product industry.

In the future, Sinopharm Kunming Plasma-Derived Biotherapies will stay committed to guaranteeing domestic demand for plasma-derived medicinal products, and expand its presence in South Asian and Southeastern Asian states. It will sharpen the core competitiveness of Yunnan's biopharmaceutical industry, and give full play to its functions in the implementation of the country's Healthy China initiative and the consolidation of the country's biological and medical security.